RE:RE:RE:RE:RE:Aside from share price ... smells right for some bolt-onsMrMugsy wrote: Hahaha - my response has been removed because of a human rights violation.
My word !
Short answer ...
I am hoping for 15% growth y-o-y by the time I sell my shares - that's my goal
Slow accumulation until then.
Shareholders might get upset - doesn't matter.
This company is in the hands of a few - making sure ROW gets built and execulted to plan.
The endgame is what matters to them - not what happens one year to the next.
The money is made later.
What we're lacking is excited investors - they are not coming for a while yet.
You will know when they are coming - all Analysts will be excited as they talk about this company.
We're not there.
Just like PLB - this is a very long and lonely road.
It's deja vu all over again (2004-2007). Fun started in 2010 and peaked in 2014.
It isn't pretty and this investment isn't for everyone. Lots of angry investors who are not investors anymore. That is the characteristic of a drug marketing firm. Now we're talking about a global ROW drug marketing firm.
- but -
We're not even global yet. By them, maybe there will be more excitement. Will see.
Knowing that - how do you invest in this one? The choice is yours.
That's all I've been saying since 2015. Undertsand it to know the best way to invest in it. Realize they are asking for a decade to build it - and - no one cares about it until everyone cares. That's the exitement. That's why I'm here.
No it is not Palladin 2.0, I think you oversimplify. GUD had never been a microcap, they raised too much money and capital has been dead capital for too long